Holen Sie sich die Stockscreener-App
84.66
5.62%
-5.09
Handel nachbörslich:
84.66
Schlusskurs vom Vortag:
$89.75
Offen:
$89.32
24-Stunden-Volumen:
512.66K
Relative Volume:
1.18
Marktkapitalisierung:
$5.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-21.71
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+1.60%
1M Leistung:
+5.27%
6M Leistung:
+21.01%
1J Leistung:
-17.99%
1-Tages-Spanne:
$84.62
$89.32
1-Wochen-Bereich:
$82.50
$89.88
52-Wochen-Spanne:
$55.53
$105.13
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
84.66 | 6.47B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Regression analysis insights on Nuvalent Inc. performanceIPO Watch & Fast Moving Market Watchlists - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Nuvalent to present new data on HER2 inhibitor at cancer conference - Investing.com Nigeria
Nuvalent to present new data on HER2 inhibitor at cancer conference By Investing.com - Investing.com South Africa
Preclinical intracranial activity: Nuvalent’s NVL-330 to be presented at AACR‑NCI‑EORTC Oct 24 - Stock Titan
Will Nuvalent Inc. stock rally after Fed decisionsJuly 2025 Weekly Recap & Low Risk Investment Opportunities - newser.com
How Nuvalent Inc. stock reacts to oil pricesBond Market & Entry Point Confirmation Signals - newser.com
What moving averages say about Nuvalent Inc.Trade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Custom strategy builders for tracking Nuvalent Inc.Weekly Trade Review & Verified Short-Term Plans - newser.com
Forecasting Nuvalent Inc. price range with options data2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 32% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Nuvalent To Participate In The UBS 2025 Virtual Oncology Day - Barchart.com
Is Nuvalent Inc. stock bottoming outVolume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Nuvalent (NASDAQ:NUVL) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Can trapped investors hope for a rebound in Nuvalent Inc.July 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Nuvalent Inc. stock trendline breakdown2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is Nuvalent Inc. showing signs of accumulationJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
What MACD signals say about Nuvalent Inc.Trade Entry Report & Risk Managed Investment Strategies - newser.com
Intraday pattern recognizer results for Nuvalent Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - newser.com
Is Nuvalent Inc. stock a buy before product launchesMarket Trend Review & Precise Buy Zone Tips - newser.com
The Escalator: Eli Lilly, Nuvalent, Lumen Bioscience and more - Medical Marketing and Media
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year - Investing.com
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating - 富途牛牛
Nuvalent, Inc. (NUVL) Stock Analysis: Promising Biotech With 38% Upside Potential - DirectorsTalk Interviews
What to expect from Nuvalent Inc. in the next 30 daysJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Will Nuvalent Inc. stock outperform Dow Jones index2025 Key Lessons & AI Driven Price Predictions - newser.com
Is Nuvalent Inc. reversing from oversold territoryQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
Analyzing net buyer seller activity in Nuvalent Inc.Quarterly Risk Review & Free Expert Approved Momentum Trade Ideas - newser.com
Nuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider Sale - Quiver Quantitative
Nuvalent chief development officer Noci sells $332k in shares By Investing.com - Investing.com UK
Nuvalent CFO Balcom sells $2.3m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent chief development officer Noci sells $332k in shares - Investing.com India
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
8.82 |
20,000 |
176,485 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Oct 01 '25 |
Sale |
85.48 |
20,000 |
1,709,512 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Option Exercise |
6.89 |
20,000 |
137,800 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Option Exercise |
6.89 |
7,588 |
52,281 |
69,322 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Sale |
85.06 |
20,000 |
1,701,200 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Sale |
85.01 |
7,588 |
645,056 |
61,734 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Option Exercise |
27.85 |
4,000 |
111,400 |
52,034 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Sale |
83.07 |
4,000 |
332,288 |
48,034 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):